Comparative Pharmacology
Head-to-head clinical analysis: NORGESTIMATE ETHINYL ESTRADIOL versus OGEN 625.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORGESTIMATE ETHINYL ESTRADIOL versus OGEN 625.
NORGESTIMATE; ETHINYL ESTRADIOL vs OGEN .625
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing norgestimate (a progestin) and ethinyl estradiol (an estrogen). The primary mechanism is suppression of gonadotropins (FSH and LH) via negative feedback on the hypothalamic-pituitary-ovarian axis, preventing ovulation. Additional effects include thickening cervical mucus (inhibiting sperm penetration) and altering endometrial receptivity.
Estrogen replacement therapy; estrogen binds to estrogen receptors, which then translocate to the nucleus and modulate gene transcription, leading to effects such as proliferation of the endometrium and regulation of gonadotropin secretion.
Oral, one tablet daily at the same time for 21 days, followed by 7 placebo tablets.
0.625 mg orally once daily
None Documented
None Documented
Norgestimate: terminal half-life of norelgestromin (active metabolite) is 27.6 ± 7.8 hours; ethinyl estradiol: terminal half-life is 17.5 ± 6.3 hours. Steady state achieved within 14 days.
Estrone: 10-24 hours; equilin: 12-18 hours; terminal half-life supports once-daily dosing.
Norgestimate metabolites are primarily excreted via urine (60-80%) and feces (35-49%) as glucuronide and sulfate conjugates; ethinyl estradiol is excreted in urine (40%) and feces (60%) as conjugates.
Renal (primarily as glucuronide and sulfate conjugates, ~50-80% of a dose), fecal (~10-20%), with enterohepatic recirculation.
Category D/X
Category C
Progestin + Estrogen
Estrogen